Bio4T2 announces CAR-T vaccination for the first patient

Bio4t2 inoculated the first patient with T cells containing chimeric antigen receptors (CARs), targeting BT-001 antigen overexpression
present in multiple types of solid tumors.
CAR-T (B4t2-001) was developed
by Bio4t2's PrismCore™ platform.

"This first-in-human study marks the evaluation of an initial therapy based on this Bio4t2 technology," said
Laurence Cooper, MD, Executive Chairman of the Board.
"PrismCore's ability to rapidly generate CAR-T that safely targets autoantigens opens up a new frontier
for the provision of CAR-T for the treatment of many types of solid tumors.
This clinical trial is at the forefront of CAR-T biology and provides an avenue for treating a large number of patients with invasive cancers worldwide," added
Dr.
Cooper.

"We are excited to begin clinical trials of the first CAR-T therapy against BT-001, a novel antigen for the therapy," said
Dr.
Farzad Haerizadeh, Chief Scientific Officer and co-founder.
"Our CAR-T was calibrated by PrismCore to distinguish between the level
of BT-001 on tumors and healthy cells.
In fact, B4t2-001 has safely demonstrated potent antitumor activity and long-term protective ability
in preclinical studies in rodents and non-human primates.
This trial helps validate the platform to enable the development of safe and effective CAR-T therapies for multiple types of solid tumors," said
Haerizadeh.